Artikel ; Online: Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
2022 Band 34, Heft 5, Seite(n) 540–545
Abstract: Purpose of review: Treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) underwent paradigm shifts, with targeted agents rapidly displacing chemotherapy. Phosphoinotiside-3 kinase (PI3K) is essential for survival and ... ...
Abstract | Purpose of review: Treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) underwent paradigm shifts, with targeted agents rapidly displacing chemotherapy. Phosphoinotiside-3 kinase (PI3K) is essential for survival and proliferation of neoplastic B cells and has proven a tractable target in NHL, with four agents receiving FDA approval in the last decade. This review summarizes key data and challenges associated with use of PI3K inhibitors in routine practice. Recent findings: Idelalisib and duvelisib are active in CLL and indolent NHL, including in patients with high-risk features. Despite differential targeting of PI3K isoforms, they exhibit comparable efficacy and adverse event profile including autoimmune events (transaminitis, colitis, pneumonitis), mediated by Treg/Th17 imbalance. Although copanlisib, a pan-PI3K inhibitor, is associated with a distinct safety profile (hyperglycemia, hypertension), preclinical studies indicate that umbralisib, a dual inhibitor of PI3Kδ and casein kinase 1ε, may have less effect on Tregs. However, both drugs may still cause immune-mediated toxicities. Summary: With close monitoring and management of adverse events, PI3K inhibitors continue to have a role in therapy of R/R CLL and NHL. Strategies to mitigate adverse events and increase efficacy of PI3K inhibitors include time-limited combination approaches, intermittent dosing schedules. |
---|---|
Mesh-Begriff(e) | Antineoplastic Agents/adverse effects ; Hematologic Neoplasms/drug therapy ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Phosphatidylinositol 3-Kinases ; Phosphoinositide-3 Kinase Inhibitors |
Chemische Substanzen | Antineoplastic Agents ; Phosphoinositide-3 Kinase Inhibitors |
Sprache | Englisch |
Erscheinungsdatum | 2022-07-16 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article ; Review ; Research Support, Non-U.S. Gov't |
ZDB-ID | 1049384-0 |
ISSN | 1531-703X ; 1040-8746 |
ISSN (online) | 1531-703X |
ISSN | 1040-8746 |
DOI | 10.1097/CCO.0000000000000871 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 3046: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.